The investor''s presentation for the quarter and nine months ended on December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Innovassynth Technologies filed its Q3 FY26 investor presentation, reporting revenue of INR 22 Cr for the quarter and INR 52 Cr for the nine-month period. The company posted an EBITDA loss of INR 4.5 Cr in Q3 and a much wider YTD loss of INR 31 Cr, with a PAT loss of INR 7.5 Cr for the quarter and INR 40.6 Cr YTD, indicating significant ongoing financial stress. The company operates three business segments — Life Sciences & Nucleosides, Specialty Chemicals, and CRDMO — and is heavily export-oriented, with about 90% of revenue coming from international markets. Geographic mix is shifting toward the US (39% YTD vs 35% FY25) and EU (26% vs 22%). The company disclosed a strong order book of INR 146 Cr, including recently secured new orders from US-based companies.
Despite a healthy order pipeline of INR 146 Cr providing future revenue visibility, the deepening YTD losses (PAT loss of INR 40.6 Cr) and weak quarterly profitability are red flags for existing shareholders. The shift toward higher-revenue US/EU markets and new US order wins are positives, but near-term earnings remain under pressure and the stock may stay volatile until order conversion shows up in revenue.